0001213900-24-046727.txt : 20240524 0001213900-24-046727.hdr.sgml : 20240524 20240524171010 ACCESSION NUMBER: 0001213900-24-046727 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 14 CONFORMED PERIOD OF REPORT: 20240522 ITEM INFORMATION: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing ITEM INFORMATION: Regulation FD Disclosure ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20240524 DATE AS OF CHANGE: 20240524 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Avalon GloboCare Corp. CENTRAL INDEX KEY: 0001630212 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 471685128 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-38728 FILM NUMBER: 24985457 BUSINESS ADDRESS: STREET 1: 4400 ROUTE 9 STREET 2: SUITE 3100 CITY: FREEHOLD STATE: NJ ZIP: 07728 BUSINESS PHONE: 732-780-4400 MAIL ADDRESS: STREET 1: 4400 ROUTE 9 STREET 2: SUITE 3100 CITY: FREEHOLD STATE: NJ ZIP: 07728 FORMER COMPANY: FORMER CONFORMED NAME: Avalon Globocare Corp. DATE OF NAME CHANGE: 20161018 FORMER COMPANY: FORMER CONFORMED NAME: GLOBAL TECHNOLOGIES CORP DATE OF NAME CHANGE: 20150108 8-K 1 ea020673001-8k_avalon.htm CURRENT REPORT
false 0001630212 0001630212 2024-05-22 2024-05-22 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

FORM 8-K

 

CURRENT REPORT

PURSUANT TO SECTION 13 OR 15(d) OF

THE SECURITIES EXCHANGE ACT OF 1934

 

Date of Report (Date of earliest event reported): May 22, 2024

 

AVALON GLOBOCARE CORP.

(Exact name of registrant as specified in its charter)

 

Delaware   001-38728   47-1685128
(State or other jurisdiction
of incorporation)		   (Commission File Number)   (IRS Employer
Identification No.)

 

4400 Route 9 South, Suite 3100, Freehold, New Jersey   07728
(Address of principal executive offices)   (Zip Code)

 

Registrant’s telephone number, including area code: (732) 780-4400

 

N/A

(Former name or former address, if changed since last report.)

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

 

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class   Trading Symbol(s)   Name of each exchange on which registered
Common Stock, $0.0001 par value per share   ALBT   The Nasdaq Capital Market

 

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

 

☐ Emerging growth company

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

 

 

 

 

Item 3.01. Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing

 

On May 22, 2024, Avalon GloboCare Corp. (the “Company”) received a notice (the “Notice”) from the Listing Qualifications Department of The Nasdaq Stock Market LLC (“Nasdaq”) stating that the Company is not in compliance with the requirements for continued listing under Nasdaq Listing Rule 5250(c)(1) (the “Listing Rule”) because the Company has not yet filed its Quarterly Report on Form 10-Q for the fiscal quarter ended March 31, 2024 (the “Quarterly Report”) with the Securities and Exchange Commission (the “SEC”).

 

The Notice has no immediate effect on the listing or trading of the Company’s common stock on the Nasdaq Capital Market. The Notice states that the Company has 60 calendar days from the date of the Notice, or July 22, 2024, to submit a plan to regain compliance with the Listing Rule. If Nasdaq accepts the Company’s plan to regain compliance, then Nasdaq may grant the Company up to 180 calendar days from the prescribed due date of the Quarterly Report, or November 18, 2024, to file the Quarterly Report to regain compliance.

 

The Company continues to work diligently to finalize its Quarterly Report and plans to file its Quarterly Report as promptly as possible to regain compliance with the Listing Rule.

 

Item 7.01. Regulation FD Disclosure  

 

A press release, dated May 24, 2024, disclosing the Company’s receipt of the Notice referenced above is attached hereto as Exhibit 99.1 and incorporated herein by reference.

 

The information furnished in this Item 7.01 of this Current Report on Form 8-K (including Exhibit 99.1 attached hereto) shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, and shall not be incorporated by reference into any filing of the Company under the Securities Act of 1933, as amended, except as shall be expressly set forth by specific reference in such filing.

 

Cautionary Statement Regarding Forward-Looking Statements

 

This filing contains a number of forward-looking statements. Words such as “expect,” “will,” “working,” “plan” and variations of such words and similar future or conditional expressions are intended to identify forward-looking statements. These forward-looking statements include, but are not limited to, statements regarding the Company’s beliefs and expectations relating to the filing of its Quarterly Report and to the Company’s ability to regain compliance with the Nasdaq Listing Rule. These forward-looking statements are not guarantees of future results and are subject to a number of risks and uncertainties, many of which are difficult to predict and beyond the Company’s control. Important factors that may cause actual results to differ materially from those in the forward-looking statements include, but are not limited to, a material delay in the Company’s financial reporting, including the possibility that the Company will not be able to promptly file its Quarterly Report, the Company’s independent auditor’s ability to finalize its review of the consolidated financial statements of the Company and the Quarterly Report in a timely manner, the Company’s ability to respond in a timely and satisfactory manner to the inquiries by Nasdaq, the Company’s ability to regain compliance with the Nasdaq Listing Rule, the Company’s ability to become current with its reports with the SEC and other factors described more fully in the Company’s periodic filings with the SEC. The Company disclaims and does not undertake any obligation to update or revise any forward-looking statement in this report, except as required by applicable law or regulation.

 

1

 

 

Item 9.01 Financial Statements and Exhibits

 

(d) Exhibits

 

Exhibit No.   Description of Exhibit
     
99.1   Press release, dated May 24, 2024.
104   Cover Page Interactive Data File - the cover page XBRL tags are embedded within the Inline XBRL document.

 

2 

 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

 
AVALON GLOBOCARE CORP. 
     
Dated: May 24, 2024 By: /s/ Luisa Ingargiola
  Name:  Luisa Ingargiola
  Title: Chief Financial Officer

 

 

3

 EX-99.1 2 ea020673001ex99-1_avalon.htm PRESS RELEASE, DATED MAY 24, 2024

 

 

Exhibit 99.1

 

Avalon GloboCare Corp. Receives Notice from Nasdaq Regarding Delayed Quarterly Report

 

FREEHOLD, N.J., May 24, 2024 (GLOBE NEWSWIRE) -- Avalon GloboCare Corp. (“Avalon” or the “Company”) (NASDAQ: ALBT), a developer of innovative cell-based technology, cellular therapy and precision diagnostics, today announced that it received a notice (the “Notice”) on May 22, 2024 from The Nasdaq Stock Market LLC (“Nasdaq”) stating that the Company is not in compliance with the requirements for continued listing under Nasdaq Listing Rule 5250(c)(1) (the “Listing Rule”) because the Company has not yet filed its Quarterly Report on Form 10-Q for the fiscal quarter ended March 31, 2024 (the “Quarterly Report”) with the Securities and Exchange Commission (the “SEC”).

 

The Notice has no immediate effect on the listing or trading of the Company’s common stock on the Nasdaq Capital Market. The Notice states that the Company has 60 calendar days from the date of the Notice, or July 22, 2024, to submit a plan to regain compliance with the Listing Rule. If Nasdaq accepts the Company’s plan to regain compliance, then Nasdaq may grant the Company up to 180 calendar days from the prescribed due date of the Quarterly Report, or November 18, 2024, to file the Quarterly Report to regain compliance.

 

The Company continues to work diligently to finalize its Quarterly Report and plans to file its Quarterly Report as promptly as possible to regain compliance with the Listing Rule.

 

This announcement is made in compliance with Nasdaq Listing Rule 5810(b), which requires prompt disclosure of receipt of a deficiency notification.

 

About Avalon GloboCare Corp.

 

Avalon GloboCare Corp. (NASDAQ: ALBT) is a commercial stage company dedicated to developing and delivering innovative, transformative, precision diagnostics and clinical laboratory services. Avalon is working to establish a leading role in the innovation of diagnostic testing, utilizing proprietary technology to deliver precise, genetics-driven results. The Company also provides laboratory services, offering a broad portfolio of diagnostic tests including drug testing, toxicology, and a broad array of test services, from general bloodwork to anatomic pathology, and urine toxicology. For more information about Avalon GloboCare, please visit www.avalon-globocare.com.

 

For the latest updates on Avalon GloboCare’s developments, please follow our twitter at @avalongc_avco.

 

Forward-Looking Statements

 

This press release contains a number of forward-looking statements. Words such as “expect,” “will,” “working,” “plan” and variations of such words and similar future or conditional expressions are intended to identify forward-looking statements. These forward-looking statements include, but are not limited to, statements regarding the Company’s beliefs and expectations relating to the filing of its Quarterly Report and to the Company’s ability to regain compliance with the Nasdaq Listing Rule. These forward-looking statements are not guarantees of future results and are subject to a number of risks and uncertainties, many of which are difficult to predict and beyond the Company’s control. Important factors that may cause actual results to differ materially from those in the forward-looking statements include, but are not limited to, a material delay in the Company’s financial reporting, including the possibility that the Company will not be able to promptly file its Quarterly Report , the Company’s independent auditor’s ability to finalize its review of the unaudited consolidated financial statements of the Company and the Quarterly Report in a timely manner, the Company’s ability to respond in a timely and satisfactory manner to the inquiries by Nasdaq, the Company’s ability to regain compliance with the Nasdaq Listing Rule, the Company’s ability to become current with its reports with the SEC and other factors described more fully in the Company’s periodic filings with the SEC. The Company disclaims and does not undertake any obligation to update or revise any forward-looking statement in this press release, except as required by applicable law or regulation.

 

 

 

Contact Information:
Avalon GloboCare Corp.
4400 Route 9, Suite 3100
Freehold, NJ 07728
PR@Avalon-GloboCare.com    

 

Investor Relations:
Crescendo Communications, LLC
Tel: (212) 671-1020 Ext. 304
albt@crescendo-ir.com    

 

 

 

 

 

 EX-101.SCH 3 albt-20240522.xsd XBRL SCHEMA FILE 00000001 - Document - Cover link:presentationLink link:calculationLink link:definitionLink EX-101.LAB 4 albt-20240522_lab.xml XBRL LABEL FILE Cover [Abstract] Document Type Amendment Flag Amendment Description Document Registration Statement Document Annual Report Document Quarterly Report Document Transition Report Document Shell Company Report Document Shell Company Event Date Document Period Start Date Document Period End Date Document Fiscal Period Focus Document Fiscal Year Focus Current Fiscal Year End Date Entity File Number Entity Registrant Name Entity Central Index Key Entity Primary SIC Number Entity Tax Identification Number Entity Incorporation, State or Country Code Entity Address, Address Line One Entity Address, Address Line Two Entity Address, Address Line Three Entity Address, City or Town Entity Address, State or Province Entity Address, Country Entity Address, Postal Zip Code Country Region City Area Code Local Phone Number Extension Written Communications Soliciting Material Pre-commencement Tender Offer Pre-commencement Issuer Tender Offer Title of 12(b) Security No Trading Symbol Flag Trading Symbol Security Exchange Name Title of 12(g) Security Security Reporting Obligation Annual Information Form Audited Annual Financial Statements Entity Well-known Seasoned Issuer Entity Voluntary Filers Entity Current Reporting Status Entity Interactive Data Current Entity Filer Category Entity Small Business Entity Emerging Growth Company Elected Not To Use the Extended Transition Period Document Accounting Standard Other Reporting Standard Item Number Entity Shell Company Entity Public Float Entity Bankruptcy Proceedings, Reporting Current Entity Common Stock, Shares Outstanding Documents Incorporated by Reference [Text Block] EX-101.PRE 5 albt-20240522_pre.xml XBRL PRESENTATION FILE XML 7 R1.htm IDEA: XBRL DOCUMENT v3.24.1.1.u2
Cover
May 22, 2024
Cover [Abstract]  
Document Type 8-K
Amendment Flag false
Document Period End Date May 22, 2024
Entity File Number 001-38728
Entity Registrant Name AVALON GLOBOCARE CORP.
Entity Central Index Key 0001630212
Entity Tax Identification Number 47-1685128
Entity Incorporation, State or Country Code DE
Entity Address, Address Line One 4400 Route 9 South
Entity Address, Address Line Two Suite 3100
Entity Address, City or Town Freehold
Entity Address, State or Province NJ
Entity Address, Postal Zip Code 07728
City Area Code (732)
Local Phone Number 780-4400
Written Communications false
Soliciting Material false
Pre-commencement Tender Offer false
Pre-commencement Issuer Tender Offer false
Title of 12(b) Security Common Stock, $0.0001 par value per share
Trading Symbol ALBT
Security Exchange Name NASDAQ
Entity Emerging Growth Company false
EXCEL 8 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 9 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 10 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 12 FilingSummary.xml IDEA: XBRL DOCUMENT 3.24.1.1.u2 html 1 23 1 false 0 0 false 3 false false R1.htm 00000001 - Document - Cover Sheet http://avalon-globocare.com/role/Cover Cover Cover 1 false false All Reports Book All Reports albt-20240522.xsd albt-20240522_lab.xml albt-20240522_pre.xml ea020673001-8k_avalon.htm http://xbrl.sec.gov/dei/2023 true false JSON 14 MetaLinks.json IDEA: XBRL DOCUMENT { "version": "2.2", "instance": { "ea020673001-8k_avalon.htm": { "nsprefix": "ALBT", "nsuri": "http://avalon-globocare.com/20240522", "dts": { "schema": { "local": [ "albt-20240522.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-roles-2023.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-types-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-roles-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-types-2023.xsd", "https://xbrl.sec.gov/country/2023/country-2023.xsd", "https://xbrl.sec.gov/dei/2023/dei-2023.xsd" ] }, "labelLink": { "local": [ "albt-20240522_lab.xml" ] }, "presentationLink": { "local": [ "albt-20240522_pre.xml" ] }, "inline": { "local": [ "ea020673001-8k_avalon.htm" ] } }, "keyStandard": 23, "keyCustom": 0, "axisStandard": 0, "axisCustom": 0, "memberStandard": 0, "memberCustom": 0, "hidden": { "total": 2, "http://xbrl.sec.gov/dei/2023": 2 }, "contextCount": 1, "entityCount": 1, "segmentCount": 0, "elementCount": 59, "unitCount": 3, "baseTaxonomies": { "http://xbrl.sec.gov/dei/2023": 23 }, "report": { "R1": { "role": "http://avalon-globocare.com/role/Cover", "longName": "00000001 - Document - Cover", "shortName": "Cover", "isDefault": "true", "groupType": "document", "subGroupType": "", "menuCat": "Cover", "order": "1", "firstAnchor": { "contextRef": "AsOf2024-05-22", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "b", "p", "body", "html" ], "reportCount": 1, "baseRef": "ea020673001-8k_avalon.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "AsOf2024-05-22", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "b", "p", "body", "html" ], "reportCount": 1, "baseRef": "ea020673001-8k_avalon.htm", "first": true, "unique": true } } }, "tag": { "dei_AmendmentDescription": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AmendmentDescription", "presentation": [ "http://avalon-globocare.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Amendment Description", "documentation": "Description of changes contained within amended document." } } }, "auth_ref": [] }, "dei_AmendmentFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AmendmentFlag", "presentation": [ "http://avalon-globocare.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Amendment Flag", "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission." } } }, "auth_ref": [] }, "dei_AnnualInformationForm": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AnnualInformationForm", "presentation": [ "http://avalon-globocare.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Annual Information Form", "documentation": "Boolean flag with value true on a form if it is an annual report containing an annual information form." } } }, "auth_ref": [ "r14" ] }, "dei_AuditedAnnualFinancialStatements": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AuditedAnnualFinancialStatements", "presentation": [ "http://avalon-globocare.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Audited Annual Financial Statements", "documentation": "Boolean flag with value true on a form if it is an annual report containing audited financial statements." } } }, "auth_ref": [ "r14" ] }, "dei_CityAreaCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CityAreaCode", "presentation": [ "http://avalon-globocare.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "City Area Code", "documentation": "Area code of city" } } }, "auth_ref": [] }, "dei_CountryRegion": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CountryRegion", "presentation": [ "http://avalon-globocare.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Country Region", "documentation": "Region code of country" } } }, "auth_ref": [] }, "dei_CoverAbstract": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CoverAbstract", "lang": { "en-us": { "role": { "label": "Cover [Abstract]", "documentation": "Cover page." } } }, "auth_ref": [] }, "dei_CurrentFiscalYearEndDate": { "xbrltype": "gMonthDayItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CurrentFiscalYearEndDate", "presentation": [ "http://avalon-globocare.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Current Fiscal Year End Date", "documentation": "End date of current fiscal year in the format --MM-DD." } } }, "auth_ref": [] }, "dei_DocumentAccountingStandard": { "xbrltype": "accountingStandardItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentAccountingStandard", "presentation": [ "http://avalon-globocare.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Accounting Standard", "documentation": "The basis of accounting the registrant has used to prepare the financial statements included in this filing This can either be 'U.S. GAAP', 'International Financial Reporting Standards', or 'Other'." } } }, "auth_ref": [ "r13" ] }, "dei_DocumentAnnualReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentAnnualReport", "presentation": [ "http://avalon-globocare.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Annual Report", "documentation": "Boolean flag that is true only for a form used as an annual report." } } }, "auth_ref": [ "r11", "r13", "r14" ] }, "dei_DocumentFiscalPeriodFocus": { "xbrltype": "fiscalPeriodItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentFiscalPeriodFocus", "presentation": [ "http://avalon-globocare.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Fiscal Period Focus", "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY." } } }, "auth_ref": [] }, "dei_DocumentFiscalYearFocus": { "xbrltype": "gYearItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentFiscalYearFocus", "presentation": [ "http://avalon-globocare.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Fiscal Year Focus", "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006." } } }, "auth_ref": [] }, "dei_DocumentPeriodEndDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentPeriodEndDate", "presentation": [ "http://avalon-globocare.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Period End Date", "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD." } } }, "auth_ref": [] }, "dei_DocumentPeriodStartDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentPeriodStartDate", "presentation": [ "http://avalon-globocare.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Period Start Date", "documentation": "The start date of the period covered in the document, in YYYY-MM-DD format." } } }, "auth_ref": [] }, "dei_DocumentQuarterlyReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentQuarterlyReport", "presentation": [ "http://avalon-globocare.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Quarterly Report", "documentation": "Boolean flag that is true only for a form used as an quarterly report." } } }, "auth_ref": [ "r12" ] }, "dei_DocumentRegistrationStatement": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentRegistrationStatement", "presentation": [ "http://avalon-globocare.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Registration Statement", "documentation": "Boolean flag that is true only for a form used as a registration statement." } } }, "auth_ref": [ "r0" ] }, "dei_DocumentShellCompanyEventDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentShellCompanyEventDate", "presentation": [ "http://avalon-globocare.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Shell Company Event Date", "documentation": "Date of event requiring a shell company report." } } }, "auth_ref": [ "r13" ] }, "dei_DocumentShellCompanyReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentShellCompanyReport", "presentation": [ "http://avalon-globocare.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Shell Company Report", "documentation": "Boolean flag that is true for a Shell Company Report pursuant to section 13 or 15(d) of the Exchange Act." } } }, "auth_ref": [ "r13" ] }, "dei_DocumentTransitionReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentTransitionReport", "presentation": [ "http://avalon-globocare.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Transition Report", "documentation": "Boolean flag that is true only for a form used as a transition report." } } }, "auth_ref": [ "r15" ] }, "dei_DocumentType": { "xbrltype": "submissionTypeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentType", "presentation": [ "http://avalon-globocare.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Type", "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'." } } }, "auth_ref": [] }, "dei_DocumentsIncorporatedByReferenceTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentsIncorporatedByReferenceTextBlock", "presentation": [ "http://avalon-globocare.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Documents Incorporated by Reference [Text Block]", "documentation": "Documents incorporated by reference." } } }, "auth_ref": [ "r3" ] }, "dei_EntityAddressAddressLine1": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressAddressLine1", "presentation": [ "http://avalon-globocare.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line One", "documentation": "Address Line 1 such as Attn, Building Name, Street Name" } } }, "auth_ref": [] }, "dei_EntityAddressAddressLine2": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressAddressLine2", "presentation": [ "http://avalon-globocare.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line Two", "documentation": "Address Line 2 such as Street or Suite number" } } }, "auth_ref": [] }, "dei_EntityAddressAddressLine3": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressAddressLine3", "presentation": [ "http://avalon-globocare.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line Three", "documentation": "Address Line 3 such as an Office Park" } } }, "auth_ref": [] }, "dei_EntityAddressCityOrTown": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressCityOrTown", "presentation": [ "http://avalon-globocare.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, City or Town", "documentation": "Name of the City or Town" } } }, "auth_ref": [] }, "dei_EntityAddressCountry": { "xbrltype": "countryCodeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressCountry", "presentation": [ "http://avalon-globocare.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Country", "documentation": "ISO 3166-1 alpha-2 country code." } } }, "auth_ref": [] }, "dei_EntityAddressPostalZipCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressPostalZipCode", "presentation": [ "http://avalon-globocare.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Postal Zip Code", "documentation": "Code for the postal or zip code" } } }, "auth_ref": [] }, "dei_EntityAddressStateOrProvince": { "xbrltype": "stateOrProvinceItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressStateOrProvince", "presentation": [ "http://avalon-globocare.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, State or Province", "documentation": "Name of the state or province." } } }, "auth_ref": [] }, "dei_EntityBankruptcyProceedingsReportingCurrent": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityBankruptcyProceedingsReportingCurrent", "presentation": [ "http://avalon-globocare.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Bankruptcy Proceedings, Reporting Current", "documentation": "For registrants involved in bankruptcy proceedings during the preceding five years, the value Yes indicates that the registrant has filed all documents and reports required to be filed by Section 12, 13 or 15(d) of the Securities Exchange Act of 1934 subsequent to the distribution of securities under a plan confirmed by a court; the value No indicates the registrant has not. Registrants not involved in bankruptcy proceedings during the preceding five years should not report this element." } } }, "auth_ref": [ "r6" ] }, "dei_EntityCentralIndexKey": { "xbrltype": "centralIndexKeyItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityCentralIndexKey", "presentation": [ "http://avalon-globocare.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Central Index Key", "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK." } } }, "auth_ref": [ "r2" ] }, "dei_EntityCommonStockSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityCommonStockSharesOutstanding", "presentation": [ "http://avalon-globocare.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Common Stock, Shares Outstanding", "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument." } } }, "auth_ref": [] }, "dei_EntityCurrentReportingStatus": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityCurrentReportingStatus", "presentation": [ "http://avalon-globocare.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Current Reporting Status", "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure." } } }, "auth_ref": [] }, "dei_EntityEmergingGrowthCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityEmergingGrowthCompany", "presentation": [ "http://avalon-globocare.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Emerging Growth Company", "documentation": "Indicate if registrant meets the emerging growth company criteria." } } }, "auth_ref": [ "r2" ] }, "dei_EntityExTransitionPeriod": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityExTransitionPeriod", "presentation": [ "http://avalon-globocare.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Elected Not To Use the Extended Transition Period", "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards." } } }, "auth_ref": [ "r19" ] }, "dei_EntityFileNumber": { "xbrltype": "fileNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityFileNumber", "presentation": [ "http://avalon-globocare.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity File Number", "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen." } } }, "auth_ref": [] }, "dei_EntityFilerCategory": { "xbrltype": "filerCategoryItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityFilerCategory", "presentation": [ "http://avalon-globocare.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Filer Category", "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure." } } }, "auth_ref": [ "r2" ] }, "dei_EntityIncorporationStateCountryCode": { "xbrltype": "edgarStateCountryItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityIncorporationStateCountryCode", "presentation": [ "http://avalon-globocare.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Incorporation, State or Country Code", "documentation": "Two-character EDGAR code representing the state or country of incorporation." } } }, "auth_ref": [] }, "dei_EntityInteractiveDataCurrent": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityInteractiveDataCurrent", "presentation": [ "http://avalon-globocare.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Interactive Data Current", "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files)." } } }, "auth_ref": [ "r16" ] }, "dei_EntityPrimarySicNumber": { "xbrltype": "sicNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityPrimarySicNumber", "presentation": [ "http://avalon-globocare.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Primary SIC Number", "documentation": "Primary Standard Industrial Classification (SIC) Number for the Entity." } } }, "auth_ref": [ "r14" ] }, "dei_EntityPublicFloat": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityPublicFloat", "crdr": "credit", "presentation": [ "http://avalon-globocare.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Public Float", "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter." } } }, "auth_ref": [] }, "dei_EntityRegistrantName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityRegistrantName", "presentation": [ "http://avalon-globocare.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Registrant Name", "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC." } } }, "auth_ref": [ "r2" ] }, "dei_EntityShellCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityShellCompany", "presentation": [ "http://avalon-globocare.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Shell Company", "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act." } } }, "auth_ref": [ "r2" ] }, "dei_EntitySmallBusiness": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntitySmallBusiness", "presentation": [ "http://avalon-globocare.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Small Business", "documentation": "Indicates that the company is a Smaller Reporting Company (SRC)." } } }, "auth_ref": [ "r2" ] }, "dei_EntityTaxIdentificationNumber": { "xbrltype": "employerIdItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityTaxIdentificationNumber", "presentation": [ "http://avalon-globocare.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Tax Identification Number", "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS." } } }, "auth_ref": [ "r2" ] }, "dei_EntityVoluntaryFilers": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityVoluntaryFilers", "presentation": [ "http://avalon-globocare.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Voluntary Filers", "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act." } } }, "auth_ref": [] }, "dei_EntityWellKnownSeasonedIssuer": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityWellKnownSeasonedIssuer", "presentation": [ "http://avalon-globocare.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Well-known Seasoned Issuer", "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A." } } }, "auth_ref": [ "r17" ] }, "dei_Extension": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "Extension", "presentation": [ "http://avalon-globocare.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Extension", "documentation": "Extension number for local phone number." } } }, "auth_ref": [] }, "dei_LocalPhoneNumber": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "LocalPhoneNumber", "presentation": [ "http://avalon-globocare.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Local Phone Number", "documentation": "Local phone number for entity." } } }, "auth_ref": [] }, "dei_NoTradingSymbolFlag": { "xbrltype": "trueItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "NoTradingSymbolFlag", "presentation": [ "http://avalon-globocare.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "No Trading Symbol Flag", "documentation": "Boolean flag that is true only for a security having no trading symbol." } } }, "auth_ref": [] }, "dei_OtherReportingStandardItemNumber": { "xbrltype": "otherReportingStandardItemNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "OtherReportingStandardItemNumber", "presentation": [ "http://avalon-globocare.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Other Reporting Standard Item Number", "documentation": "\"Item 17\" or \"Item 18\" specified when the basis of accounting is neither US GAAP nor IFRS." } } }, "auth_ref": [ "r13" ] }, "dei_PreCommencementIssuerTenderOffer": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "PreCommencementIssuerTenderOffer", "presentation": [ "http://avalon-globocare.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Pre-commencement Issuer Tender Offer", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act." } } }, "auth_ref": [ "r7" ] }, "dei_PreCommencementTenderOffer": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "PreCommencementTenderOffer", "presentation": [ "http://avalon-globocare.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Pre-commencement Tender Offer", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act." } } }, "auth_ref": [ "r8" ] }, "dei_Security12bTitle": { "xbrltype": "securityTitleItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "Security12bTitle", "presentation": [ "http://avalon-globocare.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Title of 12(b) Security", "documentation": "Title of a 12(b) registered security." } } }, "auth_ref": [ "r1" ] }, "dei_Security12gTitle": { "xbrltype": "securityTitleItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "Security12gTitle", "presentation": [ "http://avalon-globocare.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Title of 12(g) Security", "documentation": "Title of a 12(g) registered security." } } }, "auth_ref": [ "r5" ] }, "dei_SecurityExchangeName": { "xbrltype": "edgarExchangeCodeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "SecurityExchangeName", "presentation": [ "http://avalon-globocare.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Security Exchange Name", "documentation": "Name of the Exchange on which a security is registered." } } }, "auth_ref": [ "r4" ] }, "dei_SecurityReportingObligation": { "xbrltype": "securityReportingObligationItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "SecurityReportingObligation", "presentation": [ "http://avalon-globocare.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Security Reporting Obligation", "documentation": "15(d), indicating whether the security has a reporting obligation under that section of the Exchange Act." } } }, "auth_ref": [ "r9" ] }, "dei_SolicitingMaterial": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "SolicitingMaterial", "presentation": [ "http://avalon-globocare.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Soliciting Material", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act." } } }, "auth_ref": [ "r10" ] }, "dei_TradingSymbol": { "xbrltype": "tradingSymbolItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "TradingSymbol", "presentation": [ "http://avalon-globocare.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Trading Symbol", "documentation": "Trading symbol of an instrument as listed on an exchange." } } }, "auth_ref": [] }, "dei_WrittenCommunications": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "WrittenCommunications", "presentation": [ "http://avalon-globocare.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Written Communications", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act." } } }, "auth_ref": [ "r18" ] } } } }, "std_ref": { "r0": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12" }, "r1": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b" }, "r2": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b-2" }, "r3": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b-23" }, "r4": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "d1-1" }, "r5": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "g" }, "r6": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12, 13, 15d" }, "r7": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "13e", "Subsection": "4c" }, "r8": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "14d", "Subsection": "2b" }, "r9": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "15", "Subsection": "d" }, "r10": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Section": "14a", "Number": "240", "Subsection": "12" }, "r11": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 10-K", "Number": "249", "Section": "310" }, "r12": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 10-Q", "Number": "240", "Section": "308", "Subsection": "a" }, "r13": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Number": "249", "Section": "220", "Subsection": "f" }, "r14": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Number": "249", "Section": "240", "Subsection": "f" }, "r15": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Forms 10-K, 10-Q, 20-F", "Number": "240", "Section": "13", "Subsection": "a-1" }, "r16": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-T", "Number": "232", "Section": "405" }, "r17": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "230", "Section": "405" }, "r18": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "230", "Section": "425" }, "r19": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "7A", "Section": "B", "Subsection": "2" } } } ZIP 15 0001213900-24-046727-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001213900-24-046727-xbrl.zip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ea020673001-8k_avalon_htm.xml IDEA: XBRL DOCUMENT 0001630212 2024-05-22 2024-05-22 iso4217:USD shares iso4217:USD shares false 0001630212 8-K 2024-05-22 AVALON GLOBOCARE CORP. DE 001-38728 47-1685128 4400 Route 9 South Suite 3100 Freehold NJ 07728 (732) 780-4400 false false false false Common Stock, $0.0001 par value per share ALBT NASDAQ false